Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 5
1988 2
1989 1
1990 5
1991 5
1992 4
1993 4
1994 5
1995 5
1996 7
1997 8
1998 4
1999 6
2000 5
2001 5
2002 6
2003 5
2004 4
2005 7
2006 2
2007 2
2008 5
2009 3
2010 1
2013 1
2015 3
2017 4
2018 1
2019 1
2020 3
2021 1
2022 1
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Vascular reactivity.
Baron AD. Baron AD. Am J Cardiol. 1999 Jul 8;84(1A):25J-27J. doi: 10.1016/s0002-9149(99)00354-9. Am J Cardiol. 1999. PMID: 10418855 Review.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Finn RS, et al. Among authors: baron ad. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. J Clin Oncol. 2020. PMID: 32716739 Free PMC article. Clinical Trial.
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, Mamounas M, Fine BM, Maslyar DJ, Ungewickell A, Scher HI. Danila DC, et al. Among authors: baron ad. J Clin Oncol. 2019 Dec 20;37(36):3518-3527. doi: 10.1200/JCO.19.00646. Epub 2019 Nov 5. J Clin Oncol. 2019. PMID: 31689155 Free PMC article. Clinical Trial.
Insulin resistance and vascular function.
Baron AD. Baron AD. J Diabetes Complications. 2002 Jan-Feb;16(1):92-102. doi: 10.1016/s1056-8727(01)00209-4. J Diabetes Complications. 2002. PMID: 11872375 Review.
Impaired glucose tolerance. Why is it not a disease?
Perry RC, Baron AD. Perry RC, et al. Among authors: baron ad. Diabetes Care. 1999 Jun;22(6):883-5. doi: 10.2337/diacare.22.6.883. Diabetes Care. 1999. PMID: 10372235 Review. No abstract available.
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Ramji Z, Dubrovsky L, Llovet JM. Kudo M, et al. Among authors: baron ad. Liver Cancer. 2023 Nov 13;13(4):451-458. doi: 10.1159/000535154. eCollection 2024 Aug. Liver Cancer. 2023. PMID: 39114764 Free PMC article.
Vascular function, insulin resistance and fatty acids.
Steinberg HO, Baron AD. Steinberg HO, et al. Among authors: baron ad. Diabetologia. 2002 May;45(5):623-34. doi: 10.1007/s00125-002-0800-2. Epub 2002 Apr 4. Diabetologia. 2002. PMID: 12107742 Review.
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
King DA, Smith AR, Pineda G, Nakano M, Michelini F, Goedegebuure SP, Thyparambil S, Liao WL, McCormick A, Ju J, Cioffi M, Zhang X, Hundal J, Griffith M, Grandori C, Pollastro M, Rosati R, Margossian A, Chatterjee P, Ainge T, Flory M, Ocampo P, Chen LM, Poultsides GA, Baron AD, Chang DT, Herman JM, Gillanders WE, Park H, Hoos WA, Nichols M, Fisher GA, Kuo CJ. King DA, et al. Among authors: baron ad. JCO Precis Oncol. 2023 Apr;7:e2100489. doi: 10.1200/PO.21.00489. JCO Precis Oncol. 2023. PMID: 37079860 Free PMC article. No abstract available.
122 results